The 2021 Year in Review: HER2+ Breast Cancer is the digital version of a print publication encompasses some of the biggest data that have read out in HER2-positive breast cancer in 2021, along with expert insights in article and video format.
Dr. Davidson on the Future of HER2-Targeted Therapies in Breast Cancer
Nancy E. Davidson, MD, discusses the future of HER2-targeted therapies in breast cancer.
Dr. Hurvitz on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast Cancer with Brain Metastases
Sara A. Hurvitz, MD, discusses the benefit of trastuzumab deruxtecan in a subset of patients with HER2-positive breast cancer and active brain metastases in the phase 3 DESTINY-Breast03 trial.
Dr. Tolaney on Pivotal Trials in HER2+ Breast Cancer
Sara M. Tolaney, MD, MPH, discusses pivotal trials in HER2-positive breast cancer.
Hurvitz Reviews Pivotal Data From 2021, Previews Year Ahead in HER2+ Metastatic Breast Cancer
Dr Hurvitz sheds light on shifts in practice patterns in HER2-positive breast cancer in light of data that emerged in 2021, remaining questions regarding treatment sequencing, the importance of updates to the National Comprehensive Cancer Network guidelines in metastatic HER2-positive breast cancer, and future directions to keep an eye on in 2022.
Trastuzumab Deruxtecan Leaves Lasting Impact on Treatment Sequencing in HER2+ Metastatic Breast Cancer
Sara A. Hurvitz, MD, reflects on the past year in HER2-positive breast cancer.
Established Agents in Metastatic HER2+ Breast Cancer Become the Focus of Research in Earlier-Stage Disease
Laura Spring, MD, discusses the influence of the findings from the DESTINY-Breast03 trial with trastuzumab deruxtecan on practice patterns in HER2-positive breast cancer, updates in the management of brain metastases, and ongoing clinical trials she is keeping an eye on to move therapies into earlier lines of treatment.
Sequencing Strategies Shift in Metastatic HER2+ Breast Cancer
Ruta D. Rao, MD, discusses factors that inform treatment selection for patients with metastatic HER2-positive breast cancer, the effects key data that emerged in 2021 have had on sequencing, strategies to mitigate toxicities associated with trastuzumab deruxtecan, and remaining questions regarding sequencing that may be the focus of ongoing research effort.
Dr. Krop on Evaluating De-Escalated Treatment Strategies in HER2+ Breast Cancer
Ian E. Krop, MD, PhD, discusses the need to evaluate de-escalated treatment strategies in HER2-positive breast cancer.
Dr. Hurvitz on Progress Made With Antibody-Drug Conjugates in HER2+ Breast Cancer
Sara A. Hurvitz, MD, discusses progress made in 2021 with antibody-drug conjugates in HER2-positive breast cancer.
Dr. Rao on Incorporating Updated NCCN Guidelines Into Treatment Selection for HER2+ Breast Cancer
Ruta D. Rao, MD, discusses how the updated National Comprehensive Cancer Network guidelines have influenced treatment selection for patients with HER2-positive breast cancer.
Krop Captures 2021 Breakthroughs in Metastatic HER2+ Breast Cancer
Ian E. Krop, MD, PhD, discusses highlights from 2021 in HER2-positive breast cancer and expectations for future research in 2022.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.